SEC Comment Letter for Silence Therapeutics (SLN) — May 22, 2026
Silence Therapeutics plc
Date: May 22, 2026 · CIK: 0001479615 · Accession: 0000000000-26-005242
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295992
Letter
Re: Silence Therapeutics plc Registration Statement on Form S-3 Filed May 18, 2026 File No. 333-295992 Dear Rhonda Hellums: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions.
May 22, 2026
Rhonda Hellums Chief Financial Officer Silence Therapeutics plc 221 River Street, 9th Floor Hoboken, NJ 07030
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Denny Xu, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 22, 2026 Rhonda Hellums Chief Financial Officer Silence Therapeutics plc 221 River Street, 9th Floor Hoboken, NJ 07030 Re: Silence Therapeutics plc Registration Statement on Form S-3 Filed May 18, 2026 File No. 333-295992 Dear Rhonda Hellums: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Denny Xu, Esq. </TEXT> </DOCUMENT>